EUVIMED · CrossrefZeitschrift
Bioconjugation Insights
ISSN 2977-8301 · BioInsights Publishing, Ltd.
Neueste Artikel
Beyond the liver: how conjugation is advancing delivery for oligonucleotide therapeutics
Industry Insights: Regulatory milestones, high-volume dealmaking, and ASCO data readouts signal a landmark month for bioconjugates
Industry Insights: Bioconjugate momentum builds with wave of regulatory approvals, clinical advances, and conference data disclosures
Coil‑Tag conjugation: a next gen site‑specific ADC fabrication technology
Precision payloads: enhancing potency and selectivity
Structural design and site-specific conjugation in bispecific ADCs
Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance
From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC
Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials
Event summary of the 16th World ADC London Summit
Crossing the ADC inflection points: what separates clinical success from failure
Striking a balance between ADC safety and efficacy
Next-generation conjugates: small peptides to transform targeted cancer therapy
Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease
Industry insights, April 2025
Translating research into therapeutics: the future of ADCs in cancer therapy
Welcome to Bioconjugation Insights
Addressing the shortfalls of LNP-based delivery with conjugate modalities
Advancing ADC innovation through multidisciplinary integration
IMAPAC Biologics World Korea 2025
The 4th World ADC Asia 2025 Summit
Industry insights, June 2025
Meet the Bioconjugation Insights Editorial Board
The 4th Annual Targeted Radiopharmaceutical Summit 2025
The 3rd Annual ADC Linker & Conjugation Summit
Antibody & TIDES Summit 2025
The 4th Annual Biologics CDMO Asia 2025
The promise of antibody-oligonucleotide conjugates for neurological diseases
Biologics CDMO Europe 2025
Industry insights, September 2025
EUVIMED